TheTechno Optimist.

IAM1363Iambic Therapeutics—Iambic Therapeutics S-1/A amended IPO filing; offering price range $15-17 per share, 9.38M shares for $150M at midpointIAM1363Iambic Therapeutics—Iambic Therapeutics files for $100-150M IPO on Nasdaq; AI-native drug discovery platform advances IAM1363 to registrational trials

IAM1363

by Iambic TherapeuticsUS

Enable treatment of HER2+ brain tumors and metastases by designing a brain-penetrant small molecule where prior HER2 drugs could not reach.

PilotStage 3 of 5

Phase 1/1b basket trial for HER2+ solid tumors; registrational trial targeted 2027.

Updated 3d agoChecked 11 Oct1 update this week

Milestones

Next · Phase 1/1b interim data presentation
  1. IAM1363 discovery and optimization completed2023Complete.
  2. IND application accepted by FDA2024Complete.
  3. Phase 1/1b trial initiationQ4 2024Complete.
  4. Phase 1/1b interim data presentationTarget 2026Current milestone.
  5. Registrational trial initiationTarget Q1 2027Not yet reached.
  6. NDA submission to FDATarget Q4 2028Not yet reached.

Most important, last 3 months

Upcoming

  1. 2026Phase 1/1b interim data presentation (next)
  2. Q4 2026NASDAQ IPO listing as IAM
  3. Q1 2027Registrational trial initiation
  4. Q4 2028NDA submission to FDA
Primer